136 related articles for article (PubMed ID: 29551072)
1. Discovery and Optimization of Phosphopantetheine Adenylyltransferase Inhibitors with Gram-Negative Antibacterial Activity.
Skepper CK; Moreau RJ; Appleton BA; Benton BM; Drumm JE; Feng BY; Geng M; Hu C; Li C; Lingel A; Lu Y; Mamo M; Mergo W; Mostafavi M; Rath CM; Steffek M; Takeoka KT; Uehara K; Wang L; Wei JR; Xie L; Xu W; Zhang Q; de Vicente J
J Med Chem; 2018 Apr; 61(8):3325-3349. PubMed ID: 29551072
[TBL] [Abstract][Full Text] [Related]
2. Fragment-Based Drug Discovery of Inhibitors of Phosphopantetheine Adenylyltransferase from Gram-Negative Bacteria.
Moreau RJ; Skepper CK; Appleton BA; Blechschmidt A; Balibar CJ; Benton BM; Drumm JE; Feng BY; Geng M; Li C; Lindvall MK; Lingel A; Lu Y; Mamo M; Mergo W; Polyakov V; Smith TM; Takeoka K; Uehara K; Wang L; Wei JR; Weiss AH; Xie L; Xu W; Zhang Q; de Vicente J
J Med Chem; 2018 Apr; 61(8):3309-3324. PubMed ID: 29498517
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of phosphopantetheine adenylyltransferase.
Zhao L; Allanson NM; Thomson SP; Maclean JK; Barker JJ; Primrose WU; Tyler PD; Lewendon A
Eur J Med Chem; 2003 Apr; 38(4):345-9. PubMed ID: 12750020
[TBL] [Abstract][Full Text] [Related]
4. Discovery of inhibitors of 4'-phosphopantetheine adenylyltransferase (PPAT) to validate PPAT as a target for antibacterial therapy.
de Jonge BL; Walkup GK; Lahiri SD; Huynh H; Neckermann G; Utley L; Nash TJ; Brock J; San Martin M; Kutschke A; Johnstone M; Laganas V; Hajec L; Gu RF; Ni H; Chen B; Hutchings K; Holt E; McKinney D; Gao N; Livchak S; Thresher J
Antimicrob Agents Chemother; 2013 Dec; 57(12):6005-15. PubMed ID: 24041904
[TBL] [Abstract][Full Text] [Related]
5. Discovery and characterization of a novel class of pyrazolopyrimidinedione tRNA synthesis inhibitors.
Montgomery JI; Smith JF; Tomaras AP; Zaniewski R; McPherson CJ; McAllister LA; Hartman-Neumann S; Arcari JT; Lescoe M; Gutierrez J; Yuan Y; Limberakis C; Miller AA
J Antibiot (Tokyo); 2015 Jun; 68(6):361-7. PubMed ID: 25464974
[TBL] [Abstract][Full Text] [Related]
6. Optimization of CoaD Inhibitors against Gram-Negative Organisms through Targeted Metabolomics.
Rath CM; Benton BM; de Vicente J; Drumm JE; Geng M; Li C; Moreau RJ; Shen X; Skepper CK; Steffek M; Takeoka K; Wang L; Wei JR; Xu W; Zhang Q; Feng BY
ACS Infect Dis; 2018 Mar; 4(3):391-402. PubMed ID: 29243909
[TBL] [Abstract][Full Text] [Related]
7. Experimentally validated novel inhibitors of Helicobacter pylori phosphopantetheine adenylyltransferase discovered by virtual high-throughput screening.
Cheng CS; Jia KF; Chen T; Chang SY; Lin MS; Yin HS
PLoS One; 2013; 8(9):e74271. PubMed ID: 24040220
[TBL] [Abstract][Full Text] [Related]
8. Discovery and optimization of antibacterial AccC inhibitors.
Cheng CC; Shipps GW; Yang Z; Sun B; Kawahata N; Soucy KA; Soriano A; Orth P; Xiao L; Mann P; Black T
Bioorg Med Chem Lett; 2009 Dec; 19(23):6507-14. PubMed ID: 19875284
[TBL] [Abstract][Full Text] [Related]
9. The use of biochemical and biophysical tools for triage of high-throughput screening hits - A case study with Escherichia coli phosphopantetheine adenylyltransferase.
Miller JR; Thanabal V; Melnick MM; Lall M; Donovan C; Sarver RW; Lee DY; Ohren J; Emerson D
Chem Biol Drug Des; 2010 May; 75(5):444-54. PubMed ID: 20486930
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of novel small molecule inhibitors of the acetyltransferase activity of Escherichia coli N-acetylglucosamine-1-phosphate-uridyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU).
Sharma R; Rani C; Mehra R; Nargotra A; Chib R; Rajput VS; Kumar S; Singh S; Sharma PR; Khan IA
Appl Microbiol Biotechnol; 2016 Apr; 100(7):3071-85. PubMed ID: 26563552
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of essramycin and comparison of its antibacterial activity.
Tee EH; Karoli T; Ramu S; Huang JX; Butler MS; Cooper MA
J Nat Prod; 2010 Nov; 73(11):1940-2. PubMed ID: 21049974
[TBL] [Abstract][Full Text] [Related]
12. Discovery of pyrazolthiazoles as novel and potent inhibitors of bacterial gyrase.
Ronkin SM; Badia M; Bellon S; Grillot AL; Gross CH; Grossman TH; Mani N; Parsons JD; Stamos D; Trudeau M; Wei Y; Charifson PS
Bioorg Med Chem Lett; 2010 May; 20(9):2828-31. PubMed ID: 20356737
[TBL] [Abstract][Full Text] [Related]
13. Hydroxamic acids as potent inhibitors of Fe(II) and Mn(II) E. coli methionine aminopeptidase: biological activities and X-ray structures of oxazole hydroxamate-EcMetAP-Mn complexes.
Huguet F; Melet A; Alves de Sousa R; Lieutaud A; Chevalier J; Maigre L; Deschamps P; Tomas A; Leulliot N; Pages JM; Artaud I
ChemMedChem; 2012 Jun; 7(6):1020-30. PubMed ID: 22489069
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and antibacterial activities of 5-(pyrazin-2-yl)-4H-1,2,4-triazole-3-thiol derivatives containing Schiff base formation as FabH inhibitory.
Zhang F; Wen Q; Wang SF; Shahla Karim B; Yang YS; Liu JJ; Zhang WM; Zhu HL
Bioorg Med Chem Lett; 2014 Jan; 24(1):90-5. PubMed ID: 24332628
[TBL] [Abstract][Full Text] [Related]
15. Syntheses, structures and antibiotic activities of LpxC inhibitors based on the diacetylene scaffold.
Liang X; Lee CJ; Chen X; Chung HS; Zeng D; Raetz CR; Li Y; Zhou P; Toone EJ
Bioorg Med Chem; 2011 Jan; 19(2):852-60. PubMed ID: 21194954
[TBL] [Abstract][Full Text] [Related]
16. One-pot synthesis, biological evaluation and molecular docking studies of fused thiazolo[2,3-b]pyrimidinone-pyrazolylcoumarin hybrids.
Gondru R; Peddi SR; Manga V; Khanapur M; Gali R; Sirassu N; Bavantula R
Mol Divers; 2018 Nov; 22(4):943-956. PubMed ID: 29968120
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of the acetyltransferase domain of N-acetylglucosamine-1-phosphate-uridylyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU). Part 2: Optimization of physical properties leading to antibacterial aryl sulfonamides.
Stokes SS; Albert R; Buurman ET; Andrews B; Shapiro AB; Green OM; McKenzie AR; Otterbein LR
Bioorg Med Chem Lett; 2012 Dec; 22(23):7019-23. PubMed ID: 23099094
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5-ones as potential antimicrobial agents.
Farghaly TA; Hassaneen HM
Arch Pharm Res; 2013 May; 36(5):564-72. PubMed ID: 23446650
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of second generation MurF inhibitors based on a cyanothiophene scaffold.
Hrast M; Anderluh M; Knez D; Randall CP; Barreteau H; O'Neill AJ; Blanot D; Gobec S
Eur J Med Chem; 2014 Feb; 73():83-96. PubMed ID: 24384549
[TBL] [Abstract][Full Text] [Related]
20. Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors.
Bagdanoff JT; Chen Z; Acker M; Chen YN; Chan H; Dore M; Firestone B; Fodor M; Fortanet J; Hentemann M; Kato M; Koenig R; LaBonte LR; Liu S; Mohseni M; Ntaganda R; Sarver P; Smith T; Sendzik M; Stams T; Spence S; Towler C; Wang H; Wang P; Williams SL; LaMarche MJ
J Med Chem; 2019 Feb; 62(4):1781-1792. PubMed ID: 30688462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
